EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Aurora Spine Corporation (ASAPF) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Aurora Spine Corporation $0.13, price $0.10, upside +29.0%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · Home Canada

AS Aurora Spine Corporation logo Thin data Sep 24, 2026

Aurora Spine Corporation

ASAPF · US

SpeculativeUpside exists, but weak quality makes the signal speculative.

✓Fair value $0.1259 · Undervalued (+29.0%)
!Quality 48/100
!Mixed Growth (revenue 5y +16.3 %/yr)
!Loss-making · -3.2% net margin (TTM)
✓Moderate debt · generates free cash flow
!Trails peers (2/12)
!Narrow moat 14/100
!Evidence only low, so the estimate is less certain
!The models disagree: range $0.0630 to $0.2247
!Weak on future: 2 out of 100
Watch Aurora Spine Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.5970 $0.0699 Fair Value $0.1259 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.0699 – $0.5970 · fair‑value band $0.0630 – $0.2247 · the $0.0976 price screens below the $0.1259 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Aurora Spine in your weekly email

Every Wednesday you see whether Aurora Spine is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTR, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases.

Show more

Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTR, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases. It also provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone lumbar fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic profile while providing spinal column support and stability; and SiLo, a posterior allograft implant; and SiLO TFX, a titanium implant device for sacroiliac joint fusion. In addition, the company offers Dexa-C, a 3D printed cervical fusion device, which is a porous 3D-printed intervertebral cage that incorporates lattice pattern options to support the matching of patients' bone quality, as well as DEXA SOLO-L, a spinal device implanted in the intervertebral body space. Further, it provides TiNano, which offers a product line of lumbar fusion devices. It serves orthopaedic, neuromolecular, pain, and interventional radiological surgeons. The company was founded in 2013 and is headquartered in Toronto, Canada.

Stock analysis

Aurora Spine Corporation (ASAPF) currently trades at $0.0976, while our model-based Fair Value estimate is $0.1259, implying the stock looks roughly 22.5% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $0.1300 per share, and 5 of the 10 models we run sit above the $0.0976 price.

Bear case: the Asset-Based group reads lowest at $0.0300, and 5 of the 10 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.0630 (bear) to $0.2247 (bull), the price of $0.0976 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Aurora Spine Corporation reported revenue of $18.4M in FY2025 versus $10.5M in FY2021, a compound +14.9%/yr. Reported net income was −$731K in FY2025.

Key figures

Market cap $12.1M · P/S ratio 0.66 · EPS (TTM) $−0.0100 · Net margin −4.0% · Return on equity −15.1% · Return on assets (EBIT) −11.5% · Operating margin −3.7% · Revenue (TTM) $18.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 58% below its 52-week high and 40% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 29%, ASAPF screens cheaper than that median.

Fair Value models

Bear $0.0630 Fair Value $0.1259 Bull $0.2247
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Growth DCF $0.0600 $0.1400 $0.2600 74
FCF DCF $0.0600 $0.1300 $0.3000 73
5Y EBITDA Exit $0.0700 $0.1500 $0.2600 72
All 10 models by family
DCF Models
FCF DCF $0.0600 $0.1300 $0.3000 73
5Y Revenue Exit $0.0300 $0.0800 $0.1300 69
5Y EBITDA Exit $0.0700 $0.1500 $0.2600 72
10Y Revenue Exit $0.0400 $0.0900 $0.1600 63
10Y EBITDA Exit $0.0600 $0.1400 $0.2700 64
Multiples
EV/EBITDA $0.0700 $0.1100 $0.1400 66
EV/Revenue $0.0200 $0.0400 $0.0600 51
Asset-Based
NCAV (Graham) $0.0200 $0.0300 $0.0500 52
Growth DCF
Growth DCF $0.0600 $0.1400 $0.2600 74
Rev-Margin DCF $0.0300 $0.0700 $0.1300 68

Open the full fair value analysis →

Notify me when ASAPF reaches fair value

Put ASAPF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 48/100

Of which business quality 47 · Market factors (momentum, volatility) 19

Profitability 40
Margins and returns on capital today
Quality Growth 71
Are margins and returns improving?
Cashflow 21
Earnings quality: real cash, not paper profit
Fin. Strength 35
Balance sheet, leverage, solvency risk
Investment 97
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 4
Price trend over the last 3–12 months (market factor)
52W Momentum 9
Distance to the 52-week high (market factor)
Net Issuance 51
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−13.5% (2020) → −1.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +11.6% a year for the price.

Watch ASAPF, get fair value alerts →

Compare Aurora Spine Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 326 stocks

Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 48 · Below median
Fair Value upside +35.7% · Top 25%
Profitability
Return on assets −2.0% · Below median
Net margin (TTM) −3.2% · Below median
Operating margin (TTM) −3.7% · Below median
Growth and dividend
Revenue growth 0.4% · Below median
Balance sheet
Debt / equity 0.75× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 3.17× · Priciest 25%
P/S (TTM) 0.66× · Cheapest 25%
P/FCF 32.3× · Pricier than median
EV/EBITDA 39.9× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)81 · sector 6
FUTURE (revenue growth)2 · sector 29
PAST (return on equity)0 · sector 16
HEALTH (low debt)63 · sector 98
DIVIDEND (yield)0 · sector 39

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $98.83 $74.79 −24%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.65 $48.02 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
Siemens Healthineers AG SHL €37.86 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aurora Spine Corporation · Fair Value
$0.1259 +22%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Aurora Spine Corporation Fair Value". https://www.fairvalue-calculator.com/stock/ASAPF

Frequently asked questions

Is Aurora Spine Corporation (ASAPF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.1259 versus a price of $0.0976, about +29% upside (undervalued).
What is the fair value of ASAPF?
Our model-based fair value for Aurora Spine Corporation is $0.1259 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.0976.
What is the quality score of ASAPF?
Aurora Spine Corporation has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aurora Spine Corporation (ASAPF)?
Our model-based price target is the fair value of $0.1259 (as of Sep 24, 2026) from 10 valuation models. Cautious scenario $0.0630, optimistic scenario $0.2247. It is a calculation from audited fundamentals, not an analyst target.
What is the Aurora Spine Corporation stock forecast for 2026?
Our models put fair value at $0.1259, about +29% upside versus a price of $0.0976 (undervalued). Cautious scenario $0.0630, optimistic scenario $0.2247. The calculation is refreshed regularly with new filings.
What is the revenue of Aurora Spine Corporation (ASAPF)?
Aurora Spine Corporation reported trailing-twelve-month revenue of about $18.4M (latest available figure, as of Sep 24, 2026).
What growth is priced into Aurora Spine Corporation (ASAPF)?
For today's price to be fair in a discounted-cash-flow model, Aurora Spine Corporation would have to grow free cash flow by +14.2 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of ASAPF use?
Our models discount Aurora Spine Corporation at 9.7 %: a base by market capitalisation (nano), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Aurora Spine Corporation that is +14.2 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Aurora Spine Corporation (ASAPF) delivered so far?
Over the past 5 years revenue at Aurora Spine Corporation grew +16.3 % a year. The price currently implies +14.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Aurora Spine Corporation (ASAPF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Aurora Spine Corporation (+14.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Aurora Spine Corporation (ASAPF)?
The free-cash-flow yield on the price is 4.90 %: that much free cash flow Aurora Spine Corporation produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Aurora Spine Corporation (ASAPF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aurora Spine Corporation it is $0.1259 per share (as of Sep 24, 2026), against a price of $0.0976. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Aurora Spine Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ASAPF trades below its calculated fair value: price $0.0976, fair value $0.1259, a gap of about +29% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ASAPF?
No. The price is what the market pays today ($0.0976); the fair value is what the company's own numbers justify ($0.1259). For Aurora Spine Corporation the two are $0.0283 per share apart. That gap is exactly why we show both numbers side by side.
How much is Aurora Spine Corporation worth?
The market values Aurora Spine Corporation at about $12.1M (market capitalisation, as of Sep 24, 2026). Per share that is $0.0976; our models calculate a fair value of $0.1259 per share.
What do the bullish and bearish scenarios say about ASAPF?
Our models span a range for Aurora Spine Corporation: cautious scenario $0.0630, base $0.1259, optimistic $0.2247 per share (as of Sep 24, 2026, price $0.0976). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aurora Spine Corporation (ASAPF)?
Balance-sheet figures for Aurora Spine Corporation (as of Sep 24, 2026): return on equity −15.1%, debt of 0.75 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is ASAPF from its 52-week high?
Aurora Spine Corporation trades at $0.0976, about 58% below its 52-week high of $0.2300 and 40% above the low of $0.0699 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1259 is for.
Which stocks are comparable to Aurora Spine Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aurora Spine Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price $0.0976, calculated fair value $0.1259 (+29%), Quality Score 48/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ASAPF calculated?
We run Aurora Spine Corporation through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1259, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Aurora Spine Corporation currently trades 22 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aurora Spine Corporation (ASAPF)?
The closing price on Sep 30, 2026 was $0.0976. Our model-based fair value is $0.1259, about +29% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aurora Spine Corporation right now?
The model range is unusually wide ($0.0630 to $0.2247). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (48/100) at a price below fair value, the discount is the argument here, not the business quality. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Aurora Spine Corporation

How large is the market capitalisation of Aurora Spine Corporation (ASAPF)?
The market capitalisation of Aurora Spine Corporation is $12.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aurora Spine Corporation (ASAPF)?
The price-to-sales ratio of Aurora Spine Corporation is 0.66 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Aurora Spine Corporation (ASAPF)?
Earnings per share at Aurora Spine Corporation are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Aurora Spine Corporation (ASAPF)?
The net margin of Aurora Spine Corporation is −4.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aurora Spine Corporation (ASAPF)?
The return on equity (ROE) of Aurora Spine Corporation is −15.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aurora Spine Corporation (ASAPF)?
On an EBIT basis the return on assets of Aurora Spine Corporation is −11.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aurora Spine Corporation (ASAPF)?
The operating margin of Aurora Spine Corporation is −3.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aurora Spine Corporation (ASAPF)?
Revenue at Aurora Spine Corporation is growing +0.4% versus a year earlier (3y avg +7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Aurora Spine Corporation (ASAPF) carry?
The net debt of Aurora Spine Corporation is $2.0M (fiscal year 2025, ≈ 5.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Aurora Spine Corporation in the live analysis

One click puts Aurora Spine Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.